Is Pfizer’s Dividend Enough To Make Up For Its Stock?
For questions about this article or underlying research, email help@trefis.com.
Pfizer (PFE) sells medicines such as Eliquis and Padcev and pays a quarterly dividend to its shareholders. The stock carried a 5.9% dividend yield at the November 10, 2026 close. Over five years, though, the share price has trailed the S&P 500 by a wide margin. So once every dividend is counted, what would you guess a five-year holder made against the market?
How Far Has Pfizer Stock Trailed The Market?
Over the five years to November 10, 2026, Pfizer’s share price fell 35.4%, while the S&P 500 rose 62.4% on price alone. On price, Pfizer trails the market by 97.8 percentage points. Anyone judging the stock by its share price watched it lose ground for five years while the market climbed.
How Much Did Pfizer’s Dividends Add?
With dividends reinvested, a Pfizer holder lost 14.6% over the same five years. The dividends added 20.8 percentage points to the return on price alone. Payouts provided the only part of a Pfizer holder’s five-year return that made money, but the falling share price took away more than they paid.
Did The Dividends Close The Gap For Pfizer Holders?
Pfizer’s dividends added about twice as much to its five-year return as the S&P 500’s dividends added to the market’s return. But the market paid its holders dividends too, so the comparison must count them on both sides:
| Return from Nov 2, 2021 to Nov 10, 2026 | On price alone | With dividends reinvested |
|---|---|---|
| The stock | -35.4% | -14.6% |
| S&P 500 | +62.4% | +73.2% |
Before taxes and costs. The S&P 500 is measured through the SPDR S&P 500 ETF.
With dividends counted, the S&P 500 gained 73.2% over the five years, leaving Pfizer holders 87.8 percentage points behind. Pfizer’s dividends closed only about a tenth of the gap, because the market’s own dividends kept adding to its lead.
What This Means If You Own Pfizer For Income
Over the past year, Pfizer’s dividends added 8.0 percentage points to its return, against 0.9 points for the S&P 500’s. With dividends reinvested, Pfizer returned 28.2% that year, against 12.7% for the S&P 500. That is the deal an income holder takes: much more of the return arrives as cash, yet over five years that cash has not made up for a share price that fell far behind the market.
Pfizer’s Biopharma segment made up 97.8% of company revenue in fiscal 2025. Over the past twelve months, Pfizer’s free cash flow was $11.8 billion, against $9.79 billion paid in dividends. On its November 3, 2026 call, management said it aims to maintain and, over time, grow the dividend.
For an income holder, the one number to watch is the gap between Pfizer’s return with dividends and the S&P 500’s return with dividends, not the dividend on its own.
Is Your Retirement Income Built To Last?
Dividends are one part of an income plan. If you live off your portfolio, what matters is whether the whole plan holds up through a bad market. Our partner advisory firm offers a free written review of your holdings, fees and income plan.
Spot an error or want more like this? Tell us in 10 seconds.